T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...

Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...

SHR-1701 plus CAPOX chemotherapy reduced treatment delays and dose reductions compared with placebo plus CAPOX in HER2-negative gastric/GEJ cancer. The bifunctional PD-L1/TGF-β inhibitor SHR-1701, in ...